{"abstract": "Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains in light of Carl C. Icahn\u2019s attempt to win board seats at Genzyme.", "web_url": "https://dealbook.nytimes.com/2010/06/03/another-view-can-biotech-survive-icahn/", "snippet": "Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains in light of Carl C. Icahn\u2019s attempt to win board seats at Genzyme.", "lead_paragraph": "Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Another View: Can Biotech Survive Icahn?", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Science and Technology", "rank": 3, "major": "N"}, {"name": "persons", "value": "George, Bill", "rank": 4, "major": "N"}, {"name": "persons", "value": "Icahn, Carl C", "rank": 5, "major": "N"}, {"name": "persons", "value": "Mulligan, Richard", "rank": 6, "major": "N"}, {"name": "persons", "value": "Stewart, Martha", "rank": 7, "major": "N"}, {"name": "persons", "value": "Whitworth, Ralph V", "rank": 8, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 9, "major": "N"}, {"name": "organizations", "value": "AMYLIN PHARMACEUTICALS INCORPORATED", "rank": 10, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 11, "major": "N"}, {"name": "organizations", "value": "Genzyme Corp", "rank": 12, "major": "N"}, {"name": "organizations", "value": "Goldman Sachs Group", "rank": 13, "major": "N"}, {"name": "organizations", "value": "Harvard Business School", "rank": 14, "major": "N"}, {"name": "organizations", "value": "Harvard University", "rank": 15, "major": "N"}, {"name": "organizations", "value": "ImClone Systems Inc", "rank": 16, "major": "N"}, {"name": "organizations", "value": "MedImmune Inc", "rank": 17, "major": "N"}, {"name": "organizations", "value": "Medtronic Inc", "rank": 18, "major": "N"}, {"name": "organizations", "value": "National Institutes of Health", "rank": 19, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 20, "major": "N"}, {"name": "organizations", "value": "Roche Holding AG", "rank": 21, "major": "N"}], "pub_date": "2010-06-03T13:15:18+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/107ebd6e-489e-506f-97d5-3da1482cb1a2", "word_count": 901, "uri": "nyt://article/107ebd6e-489e-506f-97d5-3da1482cb1a2"}